New Drug Product: Givlaari
This slideshow shows drug information for Givlaari. Click here for the complete Givlaari monograph.
Digestive and Biliary Disorders
New Pancreaze Formulation Approved With Extended Shelf Life
The Food and Drug Administration has approved a new formulation of Pancreaze (pancrelipase; Vivus) Delayed Release Capsules which would allow for an extended shelf life of 36 months.
Givlaari Approved for Acute Hepatic Porphyria
The Food and Drug Administration has approved Givlaari (givosiran; Alnylam) for the treatment of adults with acute hepatic porphyria (AHP). AHP is a rare, genetic disease characterized by episodic and potentially life-threatening attacks. The disease is comprised of 4 subtypes that result from genetic defects affecting the heme biosynthesis pathway in the liver; this causes…
Acute Pancreatitis Linked to Black Elderberry Extract
Black elderberry extract could potentially induce pancreatitis, as described in a recent case report published in the journal Digestive Diseases and Sciences.
OTC Gel Helps Patients Who Have Trouble Swallowing Medications
Phazix, a gel designed to help patients who have difficulty swallowing medications, has been made available over-the-counter by Arkray USA. According to the Company, the thick, slippery gel is placed on a spoon with the medication and consumed in a single swallow; Phazix may be consumed with tablets, capsules, or powders, however it should not…
Liraglutide Ups Risk for Gallbladder, Biliary Tract Events
Findings consistent for gallbladder stones, cholecystitis with/without gallbladder stones, biliary obstruction.
Sponge Cytology-Sampling Device Promising for Barrett’s Esophagus Dx
Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus.
CDC: Slight Hike in Prevalence of Gastroschisis Since 2006-2010
Over time, the prevalence of gastroschisis has increased, with more babies born with gastroschisis in areas with high and medium vs low opioid prescription rates, according to new research.
Assure Slide Available for Patients With Medication Swallowing Difficulties
The gel breaks down immediately in the stomach so it does not affect the absorption rate of the medication, unlike other carriers that are used to facilitate swallowing.
First-in-Class Drug for Biliary Atresia Granted Orphan Drug Designation
Currently, there is no FDA-approved treatment for biliary atresia, a rare pediatric liver disease.
